Quick Answer
ENANTA PHARMACEUTICALS INC reported Diluted EPS of $3.84 per share (loss) for fiscal year 2025.
ENANTA PHARMACEUTICALS INC Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$3.84 | +29.9% |
| 2024 | -$5.48 | +14.1% |
| 2023 | -$6.38 | -8.0% |
| 2022 | -$5.91 | -50.8% |
| 2021 | -$3.92 | -116.6% |
| 2020 | -$1.81 | -181.9% |
| 2019 | $2.21 | -36.5% |
| 2018 | $3.48 | +282.4% |
| 2017 | $0.91 | -19.5% |
| 2016 | $1.13 | -72.4% |
| 2015 | $4.09 | +127.2% |
| 2014 | $1.80 | +368.7% |
| 2013 | -$0.67 | -159.3% |
| 2012 | $1.13 | -14.4% |
| 2011 | $1.32 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | -$0.42 | +60.0% | +50.6% |
| June 30, 2025 | -$0.85 | +20.6% | +19.8% |
| March 31, 2025 | -$1.06 | +27.9% | -1.0% |
| December 31, 2024 | -$1.05 | +33.5% | +1.9% |
| June 30, 2024 | -$1.07 | +42.5% | +27.2% |
| March 31, 2024 | -$1.47 | +17.9% | +7.0% |
| December 31, 2023 | -$1.58 | -13.7% | +15.1% |
| June 30, 2023 | -$1.86 | -21.6% | -3.9% |
- ENANTA PHARMACEUTICALS INC showed an increase of +29.9% in Diluted EPS compared to the prior fiscal year.
- Over the 2011–2025 period, ENANTA PHARMACEUTICALS INC’s diluted eps has declined by 390.9% (from $1.32 per share to $3.84 per share (loss)).
- The most recent figure is from ENANTA PHARMACEUTICALS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on November 19, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: